References
- BressingtonDStockJHulbertSMacInnesDA retrospective observational study of the effectiveness of paliperidone palmitate on acute inpatient hospitalization ratesInt Clin Psychopharmacol20153023023625882381
- ZhangFSiTChiouCFEfficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophreniaNeuropsychiatr Dis Treat20151165766825792835
- EmsleyRChilizaBAsmalLHarveyBHThe nature of relapse in schizophreniaBMC Psychiatry2013135023394123
- CaseyDELong-term treatment goals: enhancing healthy outcomesCNS Spectr20038262814978456
- AlphsLBossieCASliwaJKMaYWTurnerNOnset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post-hoc analysis of a randomized, double-blind clinical trialAnn Gen Psychiatry2011101221481243
- SubotnikKLCasausLRVenturaJLong-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trialJAMA Psychiatry20157282282926107752
- BrissosSVeguillaMRTaylorDBalanza-MartinezVThe role of long-acting injectable antipsychotics in schizophrenia: a critical appraisalTher Adv Psychopharmacol2014419821925360245
- CitromeLPaliperidone palmitate-review of the efficacy, safety and cost of a new second-generation depot antipsychotic medicationInt J Clin Pract20106421623919886879
- HoySMScottLJKeatingGMIntramuscular paliperidone palmitateCNS Drugs20102422724420155997
- OwenRTPaliperidone palmitate injection: its efficacy, safety and tolerability in schizophreniaDrugs Today (Barc)20104646347120683501
- SamtaniMNGopalSGassmann-MayerCAlphsLPalumboJMDosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial dataCNS Drugs20112582984521936586
- LafeuilleMHLaliberte-AugerFLefebvrePFroisCFastenauJDuhMSImpact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysisBMC Psychiatry20131311123281653
- LambertTOlivaresJMPeuskensJEffectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and BelgiumAnn Gen Psychiatry2011101021463526
- VelliganDIWeidenPJSajatovicMThe expert consensus guideline series: adherence problems in patients with serious and persistent mental illnessJ Clin Psychiatry20097014619686636
- LiHTurkozIZhangFEfficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative studyNeuropsychiatr Dis Treat201612152426730193
- Invega Sustenna® (Paliperidone palmitate) extended release injectable suspension [prescribing information]United StatesJanssen Pharmaceuticals Inc.2017
- MeltzerHYRisingerRNasrallahHAA randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophreniaJ Clin Psychiatry2015761085109026114240
- KimBLeeSHYangYKParkJIChungYCLong-acting injectable antipsychotics for first-episode schizophrenia: the pros and consSchizophr Res Treat20122012560836
- PandinaGJLindenmayerJPLullJA randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophreniaJ Clin Psychopharmacol20103023524420473057
- SchreinerABergmansPCherubinPPaliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychoticsJ Psychopharmacol20152991092225999398
- CañasFCiudadAGutiérrezMSafety, effectiveness, and patterns of use of olanzapine in acute schizophrenia: a multivariate analysis of a large naturalistic study in the hospital settingMed Clin2005124481486